MTOR and COVID-19: The meta-analysis also found that using mTOR inhibitors in kidney transplant patients is linked tolower odds of death from COVID-19 compared to other forms of immunosuppression (OR= 0.63, 95% CI 0.48 to 0.83, P= 0.001).